SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
SMMT shares plunged 20% overnight late Sunday after the FDA rejected its Ivonescimab-plus-chemotherapy application for a lung cancer indication.